Resources

This interview is also available as a video: click here to view. Dr. Joseph Aloi, Wake Forest Baptist Medical Center, Winston-Salem, NC. Steve: This is Steve Freed with Diabetes in Control and we’re here at AACE 2016 and we have with us a special guest who’s been working on some unique …

Guest article by David Kliff, Diabetic Investor: Panel further assessing date that SGLT-2 drug shows actual benefit for heart.

More stringent hyperglycemia management (target A1C 6-6.5%) in type 2 diabetes might be supported by which one of the following factors: A. Long-standing disease duration B. Moderate-severe vascular complications C. Shorter life expectancy D. Absent-few comorbidities Are you right? Follow the link to find out!

For many years, I have focused on aspects of lifestyle and health management that can enhance quality of life, especially when living with a chronic disease like diabetes, rather than simply on living a long time (longevity). Much of my motivation is derived from the personal experience of watching my maternal grandmother suffer through six (long) years of severe disability related to cardiovascular complications of diabetes starting at the age of 70 that left her unable to feed herself or communicate, bed bound, and with almost no quality of life for her final six years of life. Really, what is the point of simply being alive when you’re really not experiencing life under such conditions?

The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study published online by JAMA Ophthalmology.

In Part 4 of this Exclusive Interview, Dr. Joseph Aloi concludes his discussion with Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida with medical developments worth watching. Joseph Aloi, MD, is Section Chief of Endocrinology and Metabolism at Wake Forest Baptist Medical Center in …

In Part 3 of this Exclusive Interview, Diabetes in Control publisher Steve Freed talks with Dr. Joseph Aloi at the AACE 2016 convention in Orlando, Florida about the use of Glucommander to prevent insulin errors. Joseph Aloi, MD, is Section Chief of Endocrinology and Metabolism at Wake Forest Baptist Medical …

In Part 2 of this Exclusive Interview, Dr. Joseph Aloi continues his discussion with Diabetes in Control publisher Steve Freed at the AACE 2016 convention in in Orlando, Florida. Dr. Aloi responds to the concern about the complication of the dosing algorithm for patients at home. Joseph Aloi, MD, is …

In Part 1 this Exclusive Interview, Dr. Joseph Aloi joins Diabetes in Control publisher Steve Freed for a discussion at the AACE 2016 convention in in Orlando, Florida, to discuss software that can help treat diabetic ketoacidosis and reduce hypoglycemic events, and the difficulties of treating the condition. Joseph Aloi, …

In part 3 of this Exclusive Interview, Dr. Chous gives a brief tour of what's on the horizon in treating diabetic eye disease.